SUBCUTANEOUS ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS: A REAL-LIFE EXPERIENCE

Juan C. Sarmiento-Monroy, C. Villota-Eraso, M. J. Mantilla-Ribero, N. Molano-Gonzalez, M. Rodriguez-Jimenez, Adriana Rojas-Villarraga, Rubeacuten D. Mantilla

Research output: Contribution to journalArticlepeer-review

59 Scopus citations

Abstract

A total of 159 patients were included. Baseline characteristics of patients were as follows: female gender 84%, median age of 54 years (IQR 16), median disease duration 10 years (11), RF positive 96%, anti-CCP positive 89%, erosive disease 55%, median DAS28-CRP 5.0 (2), and median RAPID3 17 (10). Concomitant use of methotrexate and SC ABA monotherapy were reported at 52% and 30% respectively. Demographics and disease characteristics were similar for all groups, except for baseline DAS28-CRP, and RAPID3 in the group that switched route of administration. The interaction between time and group was significant (p = 0.0073) for RAPID3. Infections, constitutional symptoms, and headaches were the most frequent AEs. Retention rate corresponded to 60% at 48 months. The most frequent reason for drug suspension was loss of efficacy. Median time of treatment for SC ABA was 31 months (IQR 30). The only association that reached statistical significance was anti-CCP concentration [Q1–Q4] (p = 0.005). According to the Cox proportional hazard regression model, there were significant differences between survival curves for Q1 (HR 0.15; 0.03–0.64 95% CI; p = 0.0096), and Q2 (HR 0.28; 0.08–0.92 95% CI; p = 0.0363) compared to the seronegative group.

Conclusions
The results showed an improvement in RA disease activity and physical function in patients under SC ABA treatment. Patients switching from IV to SC administration of ABA had lower activity and functional impairment at baseline. SC ABA demonstrated a good safety profile consistent with previously published data. Patients with baseline levels of anti-CCP antibody concentrations had better drug survival than seronegative patients.
Translated title of the contributionAbatecept Subcutáneo en pacientes con artritis reumatoide: una experiencia en la vida real 2019
Original languageEnglish
Pages (from-to)1024-1024
JournalAnnals of the Rheumatic Diseases
Volume75
Issue number2
DOIs
StatePublished - Jun 2016

Cite this